These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32882250)

  • 21. Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies.
    Heavner MS; McCurdy MT; Mazzeffi MA; Galvagno SM; Tanaka KA; Chow JH
    J Intensive Care Med; 2021 Jun; 36(6):635-645. PubMed ID: 32223515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin II in septic shock.
    Jadhav AP; Sadaka FG
    Am J Emerg Med; 2019 Jun; 37(6):1169-1174. PubMed ID: 30935784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of Angiotensin II in Poisoning-Induced Shock-a Review.
    Chen A; Wong A
    J Med Toxicol; 2022 Apr; 18(2):145-154. PubMed ID: 35258848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis.
    Dünser MW; Mayr AJ; Ulmer H; Ritsch N; Knotzer H; Pajk W; Luckner G; Mutz NJ; Hasibeder WR
    Anesth Analg; 2001 Jul; 93(1):7-13. PubMed ID: 11429329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data.
    Abril MK; Khanna AK; Kroll S; McNamara C; Handisides D; Busse LW
    J Crit Care; 2019 Apr; 50():188-194. PubMed ID: 30553989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study.
    Chawla LS; Busse L; Brasha-Mitchell E; Davison D; Honiq J; Alotaibi Z; Seneff MG
    Crit Care; 2014 Oct; 18(5):534. PubMed ID: 25286986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Vasopressin for Septic Shock in Patients on Chronic Renin-Angiotensin-Aldosterone System Inhibitors.
    Erwin BL; Denaburg MA; Barker AB; McArdle PJ; Windham ST; Morgan CJ
    Crit Care Med; 2017 Dec; 45(12):e1226-e1232. PubMed ID: 28991825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of continuous vasopressin infusion in patients with septic shock.
    Obritsch MD; Jung R; Fish DN; MacLaren R
    Ann Pharmacother; 2004; 38(7-8):1117-22. PubMed ID: 15178740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial.
    Chawla LS; Russell JA; Bagshaw SM; Shaw AD; Goldstein SL; Fink MP; Tidmarsh GF
    Crit Care Resusc; 2017 Mar; 19(1):43-49. PubMed ID: 28215131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful Treatment of Antihypertensive Overdose Using Intravenous Angiotensin II.
    Carpenter JE; Murray BP; Saghafi R; Thomas B; Lee S; Kleiman R; Punja M; Silver E; Busse LW
    J Emerg Med; 2019 Sep; 57(3):339-344. PubMed ID: 31279637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roles of angiotensin II as vasopressor in vasodilatory shock.
    Lumlertgul N; Ostermann M
    Future Cardiol; 2020 Nov; 16(6):569-583. PubMed ID: 32462921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Catecholamine Vasopressor Support Sparing Strategies in Vasodilatory Shock.
    Buckley MS; Barletta JF; Smithburger PL; Radosevich JJ; Kane-Gill SL
    Pharmacotherapy; 2019 Mar; 39(3):382-398. PubMed ID: 30506565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the Addition of Angiotensin II in Patients With Shock After Cardiac Surgery at a Veterans Affairs Medical Center.
    Bird S; Chand M; Tran TL; Ali S; Awad SS; Cornwell LD; Schutz A; Jimenez E
    Ann Pharmacother; 2023 Feb; 57(2):141-147. PubMed ID: 35658717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study.
    Dünser MW; Mayr AJ; Ulmer H; Knotzer H; Sumann G; Pajk W; Friesenecker B; Hasibeder WR
    Circulation; 2003 May; 107(18):2313-9. PubMed ID: 12732600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin II for the treatment of distributive shock in the intensive care unit: A US cost-effectiveness analysis.
    Busse LW; Nicholson G; Nordyke RJ; Lee CH; Zeng F; Albertson TE
    Int J Technol Assess Health Care; 2020 Apr; 36(2):145-151. PubMed ID: 32114996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial.
    Bellomo R; Forni LG; Busse LW; McCurdy MT; Ham KR; Boldt DW; Hästbacka J; Khanna AK; Albertson TE; Tumlin J; Storey K; Handisides D; Tidmarsh GF; Chawla LS; Ostermann M
    Am J Respir Crit Care Med; 2020 Nov; 202(9):1253-1261. PubMed ID: 32609011
    [No Abstract]   [Full Text] [Related]  

  • 37. Angiotensin II: a new approach for refractory shock management?
    Kimmoun A; Levy B
    Crit Care; 2014 Dec; 18(6):694. PubMed ID: 25645552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin II for the Treatment of Refractory Shock: A Matched Analysis.
    Smith LM; Mentz GB; Engoren MC
    Crit Care Med; 2023 Dec; 51(12):1674-1684. PubMed ID: 37378469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VASOPRESSOR-RESISTANT HYPOTENSION, COMBINATION VASOPRESSOR THERAPY, AND SHOCK PHENOTYPES IN CRITICALLY ILL ADULTS WITH VASODILATORY SHOCK.
    Priyanka P; Chang CH; Chawla LS; Kellum JA; Clermont G; Murugan R
    Shock; 2022 Oct; 58(4):260-268. PubMed ID: 36018286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock.
    Luckner G; Mayr VD; Jochberger S; Wenzel V; Ulmer H; Hasibeder WR; Dünser MW
    Crit Care Med; 2007 Oct; 35(10):2280-5. PubMed ID: 17944015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.